Jeet Mukherjee
Stock Analyst at BTIG
(3.95)
# 1,411
Out of 5,182 analysts
45
Total ratings
57.78%
Success rate
10.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Reiterates: Buy | $19 | $5.46 | +247.99% | 4 | Apr 23, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterates: Buy | $48 | $23.00 | +108.70% | 3 | Apr 13, 2026 | |
| AARD Aardvark Therapeutics | Reiterates: Buy | $9 | $5.59 | +61.00% | 4 | Mar 24, 2026 | |
| ARVN Arvinas | Maintains: Buy | $14 → $16 | $10.22 | +56.56% | 3 | Mar 19, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $3.95 | +254.43% | 4 | Mar 17, 2026 | |
| IPHA Innate Pharma | Assumes: Buy | $8 | $1.40 | +471.43% | 1 | Mar 12, 2026 | |
| IBRX ImmunityBio | Assumes: Buy | $13 | $6.96 | +86.78% | 1 | Mar 12, 2026 | |
| AVBP ArriVent BioPharma | Assumes: Buy | $42 | $30.04 | +39.81% | 1 | Mar 12, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $138 → $134 | $83.85 | +59.81% | 6 | Feb 26, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $192 → $215 | $125.96 | +70.69% | 5 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $104 | $54.48 | +90.90% | 6 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $17.08 | +75.64% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $21.92 | +27.74% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.17 | +112.77% | 1 | Dec 18, 2025 |
Verastem
Apr 23, 2026
Reiterates: Buy
Price Target: $19
Current: $5.46
Upside: +247.99%
Ascentage Pharma Group International
Apr 13, 2026
Reiterates: Buy
Price Target: $48
Current: $23.00
Upside: +108.70%
Aardvark Therapeutics
Mar 24, 2026
Reiterates: Buy
Price Target: $9
Current: $5.59
Upside: +61.00%
Arvinas
Mar 19, 2026
Maintains: Buy
Price Target: $14 → $16
Current: $10.22
Upside: +56.56%
Perspective Therapeutics
Mar 17, 2026
Reiterates: Buy
Price Target: $14
Current: $3.95
Upside: +254.43%
Innate Pharma
Mar 12, 2026
Assumes: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
ImmunityBio
Mar 12, 2026
Assumes: Buy
Price Target: $13
Current: $6.96
Upside: +86.78%
ArriVent BioPharma
Mar 12, 2026
Assumes: Buy
Price Target: $42
Current: $30.04
Upside: +39.81%
Kymera Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $138 → $134
Current: $83.85
Upside: +59.81%
Palvella Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $192 → $215
Current: $125.96
Upside: +70.69%
Feb 23, 2026
Reiterates: Buy
Price Target: $104
Current: $54.48
Upside: +90.90%
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $17.08
Upside: +75.64%
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $21.92
Upside: +27.74%
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $5.17
Upside: +112.77%